Pfetin as a Prognostic Biomarker for Gastrointestinal Stromal Tumor: Validation Study in Multiple Clinical Facilities
Pfetin as a Prognostic Biomarker for Gastrointestinal Stromal Tumor: Validation Study in Multiple Clinical Facilities
复制标题
DOI：
10.1093/jjco/hyr121
复制
发表时间：
2011-10-01
影响因子：
2.4
通讯作者：
Kondo, Tadashi
中科院分区：
文献类型：
--
作者：
Kubota, Daisuke;Orita, Hajime;Kondo, Tadashi
目的：探讨pfetin对胃肠道间质瘤患者预后的预测价值。我们最近报道了胃肠道间质瘤的一种新的预后生物标志物pfetin的效用。胃肠道间质瘤的范围很广，从可治愈的病例到因转移和复发而致命的肿瘤。有没有生物标志物预测转移和/或复发的胃肠道间质瘤，虽然伊马替尼甲磺酸盐可以提高无复发survival.Methods：Pfetin的表达进行了检查，在40例胃肠道间质瘤患者从顺天堂大学静冈医院使用免疫组化。免疫组化结果和临床病理参数之间的相关性进行了研究。pfetin的表达结果与临床病理资料结合，共299例，其中包括40例新发胃肠道间质瘤病例和259例有既往报道的病例。免疫组化结果显示pfetin阳性的无病生存率为93.75%，pfetin阴性的为25.0%。顺天堂大学静冈医院的40例患者中，阴性患者（P = 0.0006）。pfetin阳性组的无病生存率为92.44%，阴性组为60.81%（P < 0.0001）。单因素和多因素分析均显示，pfetin表达是影响胃肠道间质瘤预后的独立因素（P < 0.05）。Pfetin似乎是一个新的临床适用的预后因素，这可能是有用的，以决定是否给予甲磺酸伊马替尼或没有。
Objective: The aim of this study is to confirm the prognostic value of pfetin in gastrointestinal stromal tumor patients. We recently reported the utility of pfetin, a novel prognostic biomarker in gastrointestinal stromal tumor. Gastrointestinal stromal tumor spans a wide spectrum from cases with curable disease to those with fatal tumors due to metastasis and recurrence. There is no biomarker predicting metastasis and/or recurrence of gastrointestinal stromal tumor though imatinib mesylate can improve recurrence-free survival.Methods: Pfetin expression was examined in 40 gastrointestinal stromal tumor patients from the Juntendo University Shizuoka Hospital using immunohistochemistry. Correlations between immunohistochemical findings and clinicopathologic parameters were examined. The pfetin expression results were integrated with the clinicopathologic data in a total of 299 cases including our 40 new gastrointestinal stromal tumor cases and 259 others with previously reported data.Results: Immunohistochemical study demonstrated the disease-free survival rate to be 93.75% for pfetin-positive and 25.0% for pfetin-negative patients among the 40 cases from the Juntendo University Shizuoka Hospital (P = 0.0006). When all 299 cases were included, the disease-free survival rate was 92.44% for pfetin-positive and 60.81% for pfetin-negative patients (P < 0.0001). Both uni- and multivariate analyses revealed that, among the clinicopathologic parameters examined, only pfetin expression was an independent prognostic factor (P < 0.05).Conclusions: These results confirm the possible clinical utility of pfetin as a prognostic biomarker for gastrointestinal stromal tumor. Pfetin appears to be a novel clinically applicable prognostic factor, which may be useful for deciding whether to administer imatinib mesylate or not.